Genetic dissection of tumor angiogenesis: Are PlGF and VEGFR-1 novel anti-cancer targets?

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1654, Issue 1, 2004, Pages 79-94

  Luttun, Aernout ^a   Autiero, Monica ^a   Tjwa, Marc ^a   Carmeliet, Peter ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Angiogenesis; Anti angiogenesis; Metastasis; PlGF; Tumor; VEGF; VEGF receptor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; CANSTATIN; ENDOSTATIN; SEMAXANIB; THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; TUMSTATIN; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; AUTOPHOSPHORYLATION; BLOOD CLOTTING DISORDER; BREAST CANCER; CANCER; CANCER THERAPY; CELL GROWTH; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CLINICAL TRIAL; COLON CANCER; FIBROSARCOMA; GENE TARGETING; GENETICS; GLIOBLASTOMA; HUMAN; HYPERTENSION; INFLAMMATION; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; NEPHROBLASTOMA; NONHUMAN; PATHOGENESIS; PHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; TUMOR GROWTH; VASCULARIZATION;

ANIMALIA;

EID: 1242269809     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2003.09.002     Document Type: Review

References (212)

1. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 9:2003;653-660.
2. Goldman E. The growth of malignant disease in man and the lower animals with special reference to the vascular system. Lancet. ii:1907;1236-1240.
3. Greenblatt M., Shubi P. Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. J. Natl. Cancer Inst. 41:1968;111-124.
4. Ehrmann R.L., Knoth M. Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studied by light and electron microscopy. J. Natl. Cancer Inst. 41:1968;1329-1341.
5. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285:1971;1182-1186.
6. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29:2002;15-18.
7. Karpanen T., Alitalo K. Lymphatic vessels as targets of tumor therapy? J. Exp. Med. 194:2001;F37-F42.
8. Pepper M.S. Lymphangiogenesis and tumor metastasis: myth or reality? Clin. Cancer Res. 7:2001;462-468.
9. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6:2000;389-395.
10. Luttun A., Carmeliet G., Carmeliet P. Vascular progenitors: from biology to treatment. Trends Cardiovasc. Med. 12:2002;88-96.
11. Rafii S., Lyden D., Benezra R., Hattori K., Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev., Cancer. 2:2002;826-835.
12. Asahara T., Isner J.M. Endothelial progenitor cells for vascular regeneration. J. Hematother. Stem Cell Res. 11:2002;171-178.
13. Wigle J.T., Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell. 98:1999;769-778.
14. Papoutsi M., Tomarev S.I., Eichmann A., Prols F., Christ B., Wilting J. Endogenous origin of the lymphatics in the avian chorioallantoic membrane. Dev. Dyn. 222:2001;238-251.
15. Baish J.W., Jain R.K. Fractals and cancer. Cancer Res. 60:2000;3683-3688.
16. Helmlinger G., Yuan F., Dellian M., Jain R.K. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med. 3:1997;177-182.
17. Jain R.K. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin. Oncol. 29:2002;3-9.
18. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., Jain R.K., McDonald D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156:2000;1363-1380.
19. Pietras K., Rubin K., Sjoblom T., Buchdunger E., Sjoquist M., Heldin C.H., Ostman A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 62:2002;5476-5484.
20. Morikawa S., Baluk P., Kaidoh T., Haskell A., Jain R.K., McDonald D.M. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160:2002;985-1000.
21. Benjamin L.E., Golijanin D., Itin A., Pode D., Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103:1999;159-165.
22. Benjamin L.E., Hemo I., Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development. 125:1998;1591-1598.
23. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111:2003;1287-1295.
24. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 279:1998;377-380.
25. Jain R.K. Determinants of tumor blood flow: a review. Cancer Res. 48:1988;2641-2658.
26. Chang Y.S., di Tomaso E., McDonald D.M., Jones R., Jain R.K., Munn L.L. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc. Natl. Acad. Sci. U. S. A. 97:2000;14608-14613.
27. Alitalo K., Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cells. 1:2002;219-227.
28. Leu A.J., Berk D.A., Lymboussaki A., Alitalo K., Jain R.K. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 60:2000;4324-4327.
29. Jain R.K. Barriers to drug delivery in solid tumors. Sci. Am. 271:1994;58-65.
30. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 26:1997;71-90.
31. Maynard S.E., Min J.Y., Merchan J., Lim K.H., Li J., Mondal S., Libermann T.A., Morgan J.P., Sellke F.W., Stillman I.E., Epstein F.H., Sukhatme V.P., Karumanchi S.A. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111:2003;649-658.
32. Kang D.H., Anderson S., Kim Y.G., Mazzalli M., Suga S., Jefferson J.A., Gordon K.L., Oyama T.T., Hughes J., Hugo C., Kerjaschki D., Schreiner G.F., Johnson R.J. Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. Am. J. Kidney Dis. 37:2001;601-611.
33. Bouck N., Stellmach V., Hsu S.C. How tumors become angiogenic. Adv. Cancer Res. 69:1996;135-174.
34. Kerbel R.S. Tumor angiogenesis: past, present and the near future. Carcinogenesis. 21:2000;505-515.
35. Carmeliet P. Developmental biology. Controlling the cellular brakes. Nature. 401:1999;657-658.
36. Fukumura D., Xavier R., Sugiura T., Chen Y., Park E.C., Lu N., Selig M., Nielsen G., Taksir T., Jain R.K., Seed B. Tumor induction of VEGF promoter activity in stromal cells. Cell. 94:1998;715-725.
37. Achen M.G., Williams R.A., Minekus M.P., Thornton G.E., Stenvers K., Rogers P.A., Lederman F., Roufail S., Stacker S.A. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. J. Pathol. 193:2001;147-154.
38. Salven P., Lymboussaki A., Heikkila P., Jaaskela-Saari H., Enholm B., Aase K., von Euler G., Eriksson U., Alitalo K., Joensuu H. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am. J. Pathol. 153:1998;103-108.
39. Stacker S.A., Caesar C., Baldwin M.E., Thornton G.E., Williams R.A., Prevo R., Jackson D.G., Nishikawa S., Kubo H., Achen M.G. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7:2001;186-191.
40. Skobe M., Hawighorst T., Jackson D.G., Prevo R., Janes L., Velasco P., Riccardi L., Alitalo K., Claffey K., Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7:2001;192-198.
41. Mandriota S.J., Jussila L., Jeltsch M., Compagni A., Baetens D., Prevo R., Banerji S., Huarte J., Montesano R., Jackson D.G., Orci L., Alitalo K., Christofori G., Pepper M.S. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 20:2001;672-682.
42. Karpanen T., Egeblad M., Karkkainen M.J., Kubo H., Yla-Herttuala S., Jaattela M., Alitalo K. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 61:2001;1786-1790.
43. Eberhard A., Kahlert S., Goede V., Hemmerlein B., Plate K.H., Augustin H.G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 60:2000;1388-1393.
44. Abramsson A., Berlin O., Papayan H., Paulin D., Shani M., Betsholtz C. Analysis of mural cell recruitment to tumor vessels. Circulation. 105:2002;112-117.
45. Sica A., Saccani A., Mantovani A. Tumor-associated macrophages: a molecular perspective. Int. Immunopharmacol. 2:2002;1045-1054.
46. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392:1998;245-252.
47. De Palma M., Venneri M.A., Roca C., Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. 9:2003;789-795.
48. Schmeisser A., Strasser R.H. Phenotypic overlap between hematopoietic cells with suggested angioblastic potential and vascular endothelial cells. J. Hematother. Stem Cell Res. 11:2002;69-79.
49. Rehman J., Li J., Orschell C.M., March K.L. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation. 107:2003;1164-1169.
50. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L., Wu Y., Hicklin D., Zhu Z., Hackett N.R., Crystal R.G., Moore M.A., Hajjar K.A., Manova K., Benezra R., Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7:2001;1194-1201.
51. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risau W., Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 380:1996;435-439.
52. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 380:1996;439-442.
53. Oosthuyse B., Moons L., Storkebaum E., Beck H., Nuyens D., Brusselmans K., Van Dorpe J., Hellings P., Gorselink M., Heymans S., Theilmeier G., Dewerchin M., Laudenbach V., Vermylen P., Raat H., Acker T., Vleminckx V., Van Den Bosch L., Cashman N., Fujisawa H., Drost M.R., Sciot R., Bruyninckx F., Hicklin D.J., Ince C., Gressens P., Lupu F., Plate K.H., Robberecht W., Herbert J.M., Collen D., Carmeliet P. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 28:2001;131-138.
54. Stalmans I., Lambrechts D., De Smet F., Jansen S., Wang J., Maity S., Kneer P., von der Ohe M., Swillen A., Maes C., Gewillig M., Molin D.G., Hellings P., Boetel T., Haardt M., Compernolle V., Dewerchin M., Plaisance S., Vlietinck R., Emanuel B., Gittenberger-de Groot A.C., Scambler P., Morrow B., Driscol D.A., Moons L., Esguerra C.V., Carmeliet G., Behn-Krappa A., Devriendt K., Collen D., Conway S.J., Carmeliet P. VEGF: a modifier of the del22q11 (DiGeorge) syndrome? Nat. Med. 9:2003;173-182.
55. Cleaver O., Krieg P.A. VEGF mediates angioblast migration during development of the dorsal aorta in Xenopus. Development. 125:1998;3905-3914.
56. Liang D., Chang J.R., Chin A.J., Smith A., Kelly C., Weinberg E.S., Ge R. The role of vascular endothelial growth factor (VEGF) in vasculogenesis, angiogenesis, and hematopoiesis in zebrafish development. Mech. Dev. 108:2001;29-43.
57. Nasevicius A., Larson J., Ekker S.C. Distinct requirements for zebrafish angiogenesis revealed by a VEGF-A morphant. Yeast. 17:2000;294-301.
58. Carmeliet P., Ng Y.S., Nuyens D., Theilmeier G., Brusselmans K., Cornelissen I., Ehler E., Kakkar V.V., Stalmans I., Mattot V., Perriard J.C., Dewerchin M., Flameng W., Nagy A., Lupu F., Moons L., Collen D., D'Amore P.A., Shima D.T. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat. Med. 5:1999;495-502.
59. Stalmans I., Ng Y.S., Rohan R., Fruttiger M., Bouche A., Yuce A., Fujisawa H., Hermans B., Shani M., Jansen S., Hicklin D., Anderson D.J., Gardiner T., Hammes H.P., Moons L., Dewerchin M., Collen D., Carmeliet P., D'Amore P.A. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J. Clin. Invest. 109:2002;327-336.
60. Maes C., Carmeliet P., Moermans K., Stockmans I., Smets N., Collen D., Bouillon R., Carmeliet G. Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech. Dev. 111:2002;61-73.
61. Mattot V., Moons L., Lupu F., Chernavvsky D., Gomez R.A., Collen D., Carmeliet P. Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice. J. Am. Soc. Nephrol. 13:2002;1548-1560.
62. Haigh J.J., Gerber H.P., Ferrara N., Wagner E.F. Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development. 127:2000;1445-1453.
63. Eremina V., Sood M., Haigh J., Nagy A., Lajoie G., Ferrara N., Gerber H.P., Kikkawa Y., Miner J.H., Quaggin S.E. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 111:2003;707-716.
64. Luttun A., Carmeliet P. Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? J. Clin. Invest. 111:2003;600-602.
65. Pettersson A., Nagy J.A., Brown L.F., Sundberg C., Morgan E., Jungles S., Carter R., Krieger J.E., Manseau E.J., Harvey V.S., Eckelhoefer I.A., Feng D., Dvorak A.M., Mulligan R.C., Dvorak H.F. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab. Invest. 80:2000;99-115.
66. Lee R.J., Springer M.L., Blanco-Bose W.E., Shaw R., Ursell P.C., Blau H.M. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation. 102:2000;898-901.
67. Dor Y., Djonov V., Abramovitch R., Itin A., Fishman G.I., Carmeliet P., Goelman G., Keshet E. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 21:2002;1939-1947.
68. Thurston G., Suri C., Smith K., McClain J., Sato T.N., Yancopoulos G.D., McDonald D.M. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science. 286:1999;2511-2514.
69. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20:2002;4368-4380.
70. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev., Cancer. 2:2002;795-803.
71. Bellamy W.T. Vascular endothelial growth factor as a target opportunity in hematological malignancies. Curr. Opin. Oncol. 14:2002;649-656.
72. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature. 407:2000;249-257.
73. Jain R.K., Carmeliet P. Vessels of death or life. Sci. Am. 285:2001;38-45.
74. Rafii S. Vaccination against tumor neovascularization: promise and reality. Cancer Cells. 2:2002;429-431.
75. Kendall R.L., Thomas K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. U. S. A. 90:1993;10705-10709.
76. Aiello L.P., Pierce E.A., Foley E.D., Takagi H., Chen H., Riddle L., Ferrara N., King G.L., Smith L.E. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. U. S. A. 92:1995;10457-10461.
77. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 362:1993;841-844.
78. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., Winkler M., Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57:1997;4593-4599.
79. Lee C.G., Heijn M., di Tomaso E., Griffon-Etienne G., Ancukiewicz M., Koike C., Park K.R., Ferrara N., Jain R.K., Suit H.D., Boucher Y. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60:2000;5565-5570.
80. Prewett M., Huber J., Li Y., Santiago A., O'Connor W., King K., Overholser J., Hooper A., Pytowski B., Witte L., Bohlen P., Hicklin D.J. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59:1999;5209-5218.
81. Strawn L.M., McMahon G., App H., Schreck R., Kuchler W.R., Longhi M.P., Hui T.H., Tang C., Levitzki A., Gazit A., Chen I., Keri G., Orfi L., Risau W., Flamme I., Ullrich A., Hirth K.P., Shawver L.K. Flk-1 as a target for tumor growth inhibition. Cancer Res. 56:1996;3540-3545.
82. Dias S., Hattori K., Heissig B., Zhu Z., Wu Y., Witte L., Hicklin D.J., Tateno M., Bohlen P., Moore M.A., Rafii S. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc. Natl. Acad. Sci. U. S. A. 98:2001;10857-10862.
83. Fong T.A., Shawver L.K., Sun L., Tang C., App H., Powell T.J., Kim Y.H., Schreck R., Wang X., Risau W., Ullrich A., Hirth K.P., McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59:1999;99-106.
84. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9:2003;669-676.
85. Suri C., Jones P.F., Patan S., Bartunkova S., Maisonpierre P.C., Davis S., Sato T.N., Yancopoulos G.D. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 87:1996;1171-1180.
86. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., Compton D., McClain J., Aldrich T.H., Papadopoulos N., Daly T.J., Davis S., Sato T.N., Yancopoulos G.D. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 277:1997;55-60.
87. Takagi H., Koyama S., Seike H., Oh H., Otani A., Matsumura M., Honda Y. Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization. Invest. Ophthalmol. Visual Sci. 44:2003;393-402.
88. Suri C., McClain J., Thurston G., McDonald D.M., Zhou H., Oldmixon E.H., Sato T.N., Yancopoulos G.D. Increased vascularization in mice overexpressing angiopoietin-1. Science. 282:1998;468-471.
89. Shim W.S., Teh M., Bapna A., Kim I., Koh G.Y., Mack P.O., Ge R. Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. Exp. Cell Res. 279:2002;299-309.
90. Hattori K., Dias S., Heissig B., Hackett N.R., Lyden D., Tateno M., Hicklin D.J., Zhu Z., Witte L., Crystal R.G., Moore M.A., Rafii S. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp. Med. 193:2001;1005-1014.
91. Visconti R.P., Richardson C.D., Sato T.N. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc. Natl. Acad. Sci. U. S. A. 99:2002;8219-8224.
92. Ahmad S.A., Liu W., Jung Y.D., Fan F., Wilson M., Reinmuth N., Shaheen R.M., Bucana C.D., Ellis L.M. The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res. 61:2001;1255-1259.
93. Thurston G., Rudge J.S., Ioffe E., Zhou H., Ross L., Croll S.D., Glazer N., Holash J., McDonald D.M., Yancopoulos G.D. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat. Med. 6:2000;460-463.
94. Carlson T.R., Feng Y., Maisonpierre P.C., Mrksich M., Morla A.O. Direct cell adhesion to the angiopoietins mediated by integrins. J. Biol. Chem. 276:2001;26516-26525.
95. Gale N.W., Thurston G., Hackett S.F., Renard R., Wang Q., McClain J., Martin C., Witte C., Witte M.H., Jackson D., Suri C., Campochiaro P.A., Wiegand S.J., Yancopoulos G.D. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev. Cell. 3:2002;411-423.
96. Hackett S.F., Wiegand S., Yancopoulos G., Campochiaro P.A. Angiopoietin-2 plays an important role in retinal angiogenesis. J. Cell. Physiol. 192:2002;182-187.
97. Pepper M.S. Extracellular proteolysis and angiogenesis. Thromb. Haemost. 86:2001;346-355.
98. Jackson C. Matrix metalloproteinases and angiogenesis. Curr. Opin. Nephrol. Hypertens. 11:2002;295-299.
99. Luttun A., Dewerchin M., Collen D., Carmeliet P. The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies. Curr. Atheroscler. Rep. 2:2000;407-416.
100. Berchem G., Glondu M., Gleizes M., Brouillet J.P., Vignon F., Garcia M., Liaudet-Coopman E. Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene. 21:2002;5951-5955.
101. Kostoulas G., Lang A., Nagase H., Baici A. Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases. FEBS Lett. 455:1999;286-290.
102. Yousef G.M., Diamandis E.P. Expanded human tissue kallikrein family - a novel panel of cancer biomarkers. Tumour Biol. 23:2002;185-192.
103. Miao R.Q., Agata J., Chao L., Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood. 100:2002;3245-3252.
104. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2:2000;737-744.
105. Devy L., Blacher S., Grignet-Debrus C., Bajou K., Masson V., Gerard R.D., Gils A., Carmeliet G., Carmeliet P., Declerck P.J., Noel A., Foidart J.M. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J. 16:2002;147-154.
106. Lambert V., Munaut C., Noel A., Frankenne F., Bajou K., Gerard R., Carmeliet P., Defresne M.P., Foidart J.M., Rakic J.M. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J. 15:2001;1021-1027.
107. Bajou K., Noel A., Gerard R.D., Masson V., Brunner N., Holst-Hansen C., Skobe M., Fusenig N.E., Carmeliet P., Collen D., Foidart J.M. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 4:1998;923-928.
108. Heymans S., Luttun A., Nuyens D., Theilmeier G., Creemers E., Moons L., Dyspersin G.D., Cleutjens J.P., Shipley M., Angellilo A., Levi M., Nube O., Baker A., Keshet E., Lupu F., Herbert J.M., Smits J.F., Shapiro S.D., Baes M., Borgers M., Collen D., Daemen M.J., Carmeliet P. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat. Med. 5:1999;1135-1142.
109. Bajou K., Masson V., Gerard R.D., Schmitt P.M., Albert V., Praus M., Lund L.R., Frandsen T.L., Brunner N., Dano K., Fusenig N.E., Weidle U., Carmeliet G., Loskutoff D., Collen D., Carmeliet P., Foidart J.M., Noel A. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J. Cell Biol. 152:2001;777-784.
110. Itoh T., Tanioka M., Yoshida H., Yoshioka T., Nishimoto H., Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58:1998;1048-1051.
111. Sounni N.E., Devy L., Hajitou A., Frankenne F., Munaut C., Gilles C., Deroanne C., Thompson E.W., Foidart J.M., Noel A. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J. 16:2002;555-564.
112. Brodsky S.V. Coagulation, fibrinolysis and angiogenesis: new insights from knockout mice. Exp. Nephrol. 10:2002;299-306.
113. Trikha M., Nakada M.T. Platelets and cancer: implications for antiangiogenic therapy. Semin. Thromb. Hemost. 28:2002;39-44.
114. Carmeliet P. Biomedicine. Clotting factors build blood vessels. Science. 293:2001;1602-1604.
115. Fernandez P.M., Rickles F.R. Tissue factor and angiogenesis in cancer. Curr. Opin. Hematol. 9:2002;401-406.
116. Ollivier V., Bentolila S., Chabbat J., Hakim J., de Prost D. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood. 91:1998;2698-2703.
117. Abe K., Shoji M., Chen J., Bierhaus A., Danave I., Micko C., Casper K., Dillehay D.L., Nawroth P.P., Rickles F.R. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc. Natl. Acad. Sci. U. S. A. 96:1999;8663-8668.
118. Zhang Y., Deng Y., Luther T., Muller M., Ziegler R., Waldherr R., Stern D.M., Nawroth P.P. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J. Clin. Invest. 94:1994;1320-1327.
119. Rickles F.R., Shoji M., Abe K. The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. Int. J. Hematol. 73:2001;145-150.
120. Carmeliet P., Lampugnani M.G., Moons L., Breviario F., Compernolle V., Bono F., Balconi G., Spagnuolo R., Oostuyse B., Dewerchin M., Zanetti A., Angellilo A., Mattot V., Nuyens D., Lutgens E., Clotman F., de Ruiter M.C., Gittenberger-de Groot A., Poelmann R., Lupu F., Herbert J.M., Collen D., Dejana E. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell. 98:1999;147-157.
121. Corada M., Zanetta L., Orsenigo F., Breviario F., Lampugnani M.G., Bernasconi S., Liao F., Hicklin D.J., Bohlen P., Dejana E. A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood. 100:2002;905-911.
122. Corada M., Mariotti M., Thurston G., Smith K., Kunkel R., Brockhaus M., Lampugnani M.G., Martin-Padura I., Stoppacciaro A., Ruco L., McDonald D.M., Ward P.A., Dejana E. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc. Natl. Acad. Sci. U. S. A. 96:1999;9815-9820.
123. Cao G., O'Brien C.D., Zhou Z., Sanders S.M., Greenbaum J.N., Makrigiannakis A., DeLisser H.M. Involvement of human PECAM-1 in angiogenesis and in vitro endothelial cell migration. Am. J. Physiol., Cell Physiol. 282:2002;C1181-C1190.
124. Hangai M., Kitaya N., Xu J., Chan C.K., Kim J.J., Werb Z., Ryan S.J., Brooks P.C. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am. J. Pathol. 161:2002;1429-1437.
125. Hynes R.O. A reevaluation of integrins as regulators of angiogenesis. Nat. Med. 8:2002;918-921.
126. Hood J.D., Cheresh D.A. Role of integrins in cell invasion and migration. Nat. Rev., Cancer. 2:2002;91-100.
127. Senger D.R., Perruzzi C.A., Streit M., Koteliansky V.E., de Fougerolles A.R., Detmar M. The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am. J. Pathol. 160:2002;195-204.
128. Reynolds L.E., Wyder L., Lively J.C., Taverna D., Robinson S.D., Huang X., Sheppard D., Hynes R.O., Hodivala-Dilke K.M. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat. Med. 8:2002;27-34.
129. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:1994;315-328.
130. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:1997;277-285.
131. Sauter B.V., Martinet O., Zhang W.J., Mandeli J., Woo S.L. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc. Natl. Acad. Sci. U. S. A. 97:2000;4802-4807.
132. Griscelli F., Li H., Bennaceur-Griscelli A., Soria J., Opolon P., Soria C., Perricaudet M., Yeh P., Lu H. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc. Natl. Acad. Sci. U. S. A. 95:1998;6367-6372.
133. Vailhe B., Feige J.J. Thrombospondins as anti-angiogenic therapeutic agents. Curr. Pharm. Des. 9:2003;583-588.
134. Streit M., Velasco P., Brown L.F., Skobe M., Richard L., Riccardi L., Lawler J., Detmar M. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am. J. Pathol. 155:1999;441-452.
135. Kyriakides T.R., Leach K.J., Hoffman A.S., Ratner B.D., Bornstein P. Mice that lack the angiogenesis inhibitor, thrombospondin 2, mount an altered foreign body reaction characterized by increased vascularity. Proc. Natl. Acad. Sci. U. S. A. 96:1999;4449-4454.
136. Kyriakides T.R., Zhu Y.H., Yang Z., Huynh G., Bornstein P. Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice. Am. J. Pathol. 159:2001;1255-1262.
137. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., Yancopoulos G.D., Wiegand S.J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 284:1999;1994-1998.
138. Bernardini G., Ribatti D., Spinetti G., Morbidelli L., Ziche M., Santoni A., Capogrossi M.C., Napolitano M. Analysis of the role of chemokines in angiogenesis. J. Immunol. Methods. 273:2003;83-101.
139. Tanaka S., Sugimachi K., Yamashita Y., Shirabe K., Shimada M., Wands J.R. Angiogenic switch as a molecular target of malignant tumors. J. Gastroenterol. 38(Suppl. 15):2003;93-97.
140. Shirakawa K., Shibuya M., Heike Y., Takashima S., Watanabe I., Konishi F., Kasumi F., Goldman C.K., Thomas K.A., Bett A., Terada M., Wakasugi H. Tumor-infiltrating endothelial cells and endothelial precursor cells in inflammatory breast cancer. Int. J. Cancer. 99:2002;344-351.
141. D'Amore P.A., Ng Y.S. Tales of the cryptic: unveiling more angiogenesis inhibitors. Trends Mol. Med. 8:2002;313-315.
142. Iliopoulos O., Levy A.P., Jiang C., Kaelin W.G. Jr., Goldberg M.A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. U. S. A. 93:1996;10595-10599.
143. Maxwell P.H., Ratcliffe P.J. Oxygen sensors and angiogenesis. Semin. Cell Dev. Biol. 13:2002;29-37.
144. Dor Y., Keshet E. Ischemia-driven angiogenesis. Trends Cardiovasc. Med. 7:1997;289-294.
145. Pugh C.W., Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 9:2003;677-684.
146. Tsuzuki Y., Fukumura D., Oosthuyse B., Koike C., Carmeliet P., Jain R.K. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha->hypoxia response element-> VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res. 60:2000;6248-6252.
147. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., Koch C.J., Ratcliffe P., Moons L., Jain R.K., Collen D., Keshert E., Keshet E. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 394:1998;485-490.
148. Maxwell P.H., Dachs G.U., Gleadle J.M., Nicholls L.G., Harris A.L., Stratford I.J., Hankinson O., Pugh C.W., Ratcliffe P.J. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. U. S. A. 94:1997;8104-8109.
149. Ryan H.E., Lo J., Johnson R.S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 17:1998;3005-3015.
150. Yu J.L., Rak J.W., Carmeliet P., Nagy A., Kerbel R.S., Coomber B.L. Heterogeneous vascular dependence of tumor cell populations. Am. J. Pathol. 158:2001;1325-1334.
151. Kondo K., Klco J., Nakamura E., Lechpammer M., Kaelin W.G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cells. 1:2002;237-246.
152. Lyden D., Young A.Z., Zagzag D., Yan W., Gerald W., O'Reilly R., Bader B.L., Hynes R.O., Zhuang Y., Manova K., Benezra R. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature. 401:1999;670-677.
153. Kliche S., Waltenberger J. VEGF receptor signaling and endothelial function. IUBMB Life. 52:2001;61-66.
154. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct. Funct. 26:2001;25-35.
155. Compernolle V., Brusselmans K., Acker T., Hoet P., Tjwa M., Beck H., Plaisance S., Dor Y., Keshet E., Lupu F., Nemery B., Dewerchin M., Van Veldhoven P., Plate K., Moons L., Collen D., Carmeliet P. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat. Med. 8:2002;702-710.
156. Le Cras T.D., Markham N.E., Tuder R.M., Voelkel N.F., Abman S.H. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am. J. Physiol., Lung Cell. Mol. Physiol. 283:2002;L555-L562.
157. LeCouter J., Moritz D.R., Li B., Phillips G.L., Liang X.H., Gerber H.P., Hillan K.J., Ferrara N. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science. 299:2003;890-893.
158. Li B., Ogasawara A.K., Yang R., Wei W., He G.W., Zioncheck T.F., Bunting S., de Vos A.M., Jin H. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension. 39:2002;1095-1100.
159. Maglione D., Guerriero V., Viglietto G., Delli Bovi P., Persico M.G. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc. Natl. Acad. Sci. U. S. A. 88:1991;9267-9271.
160. McDonald N.Q., Hendrickson W.A. A structural superfamily of growth factors containing a cystine knot motif. Cell. 73:1993;421-424.
161. Beck H., Acker T., Puschel A.W., Fujisawa H., Carmeliet P., Plate K.H. Cell type-specific expression of neuropilins in an MCA-occlusion model in mice suggests a potential role in post-ischemic brain remodeling. J. Neuropathol. Exp. Neurol. 61:2002;339-350.
162. Iyer S., Acharya K.R. Role of placenta growth factor in cardiovascular health. Trends Cardiovasc. Med. 12:2002;128-134.
163. Luttun A., Tjwa M., Moons L., Wu Y., Angelillo-Scherrer A., Liao F., Nagy J.A., Hooper A., Priller J., De Klerck B., Compernolle V., Daci E., Bohlen P., Dewerchin M., Herbert J.M., Fava R., Matthys P., Carmeliet G., Collen D., Dvorak H.F., Hicklin D.J., Carmeliet P. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 8:2002;831-840.
164. Donnini S., Machein M.R., Plate K.H., Weich H.A. Expression and localization of placenta growth factor and PlGF receptors in human meningiomas. J. Pathol. 189:1999;66-71.
165. Lacal P.M., Failla C.M., Pagani E., Odorisio T., Schietroma C., Falcinelli S., Zambruno G., D'Atri S. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J. Invest. Dermatol. 115:2000;1000-1007.
166. Park J.E., Chen H.H., Winer J., Houck K.A., Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 269:1994;25646-25654.
167. Sawano A., Takahashi T., Yamaguchi S., Aonuma M., Shibuya M. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ. 7:1996;213-221.
168. Ziche M., Maglione D., Ribatti D., Morbidelli L., Lago C.T., Battisti M., Paoletti I., Barra A., Tucci M., Parise G., Vincenti V., Granger H.J., Viglietto G., Persico M.G. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab. Invest. 76:1997;517-531.
169. Persico M.G., Vincenti V., DiPalma T. Structure, expression and receptor-binding properties of placental growth factor (PlGF). Curr. Top. Microbiol. Immunol. 237:1999;31-40.
170. Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., Heldin C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269:1994;26988-26995.
171. Cunningham S.A., Tran T.M., Arrate M.P., Bjercke R., Brock T.A. KDR activation is crucial for VEGF165-mediated Ca2+ mobilization in human umbilical vein endothelial cells. Am. J. Physiol. 276:1999;C176-C181.
172. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De Mol M., Wu Y., Bono F., Devy L., Beck H., Scholz D., Acker T., DiPalma T., Dewerchin M., Noel A., Stalmans I., Barra A., Blacher S., Vandendriessche T., Ponten A., Eriksson U., Plate K.H., Foidart J.M., Schaper W., Charnock-Jones D.S., Hicklin D.J., Herbert J.M., Collen D., Persico M.G. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7:2001;575-583.
173. Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H., Sato M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene. 5:1990;519-524.
174. Barleon B., Hauser S., Schollmann C., Weindel K., Marme D., Yayon A., Weich H.A. Differential expression of the two VEGF receptors flt and KDR in placenta and vascular endothelial cells. J. Cell. Biochem. 54:1994;56-66.
175. Ishida A., Murray J., Saito Y., Kanthou C., Benzakour O., Shibuya M., Wijelath E.S. Expression of vascular endothelial growth factor receptors in smooth muscle cells. J. Cell. Physiol. 188:2001;359-368.
176. Barleon B., Sozzani S., Zhou D., Weich H.A., Mantovani A., Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 87:1996;3336-3343.
177. Gerber H.P., Vu T.H., Ryan A.M., Kowalski J., Werb Z., Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 5:1999;623-628.
178. Nagura S., Katoh R., Miyagi E., Shibuya M., Kawaoi A. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor-1 (Flt-1) in Graves disease possibly correlated with increased vascular density. Human Pathol. 32:2001;10-17.
179. Herold-Mende C., Steiner H.H., Andl T., Riede D., Buttler A., Reisser C., Fusenig N.E., Mueller M.M. Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Lab. Invest. 79:1999;1573-1582.
180. Volm M., Koomagi R., Mattern J., Stammler G. Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro. Anticancer Res. 17:1997;99-103.
181. Takanami I., Tanaka F., Hashizume T., Kodaira S. Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res. 17:1997;2811-2814.
182. Hahn D., Simak R., Steiner G.E., Handisurya A., Susani M., Marberger M. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. J. Urol. 164:2000;506-510.
183. de Jong J.S., van Diest P.J., van der Valk P., Baak J.P. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops. J. Pathol. 184:1998;44-52.
184. Andre T., Kotelevets L., Vaillant J.C., Coudray A.M., Weber L., Prevot S., Parc R., Gespach C., Chastre E. Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int. J. Cancer. 86:2000;174-181.
185. Inoki I., Shiomi T., Hashimoto G., Enomoto H., Nakamura H., Makino Ki K., Ikeda E., Takata S., Kobayashi Ki K., Okada Y. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 14:2001;14.
186. Stefanik D.F., Fellows W.K., Rizkalla L.R., Rizkalla W.M., Stefanik P.P., Deleo A.B., Welch W.C. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J. Neurooncol. 55:2001;91-100.
187. Lin B., Podar K., Gupta D., Tai Y.T., Li S., Weller E., Hideshima T., Lentzsch S., Davies F., Li C., Weisberg E., Schlossman R.L., Richardson P.G., Griffin J.D., Wood J., Munshi N.C., Anderson K.C. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 62:2002;5019-5026.
188. Ghanem M.A., van Steenbrugge G.J., Sudaryo M.K., Mathoera R.B., Nijman J.M., van der Kwast T.H. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J. Clin. Pathol. 56:2003;107-113.
189. Gille H., Kowalski J., Li B., LeCouter J., Moffat B., Zioncheck T.F., Pelletier N., Ferrara N. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J. Biol. Chem. 276:2001;3222-3230.
190. Migdal M., Huppertz B., Tessler S., Comforti A., Shibuya M., Reich R., Baumann H., Neufeld G. Neuropilin-1 is a placenta growth factor-2 receptor. J. Biol. Chem. 273:1998;22272-22278.
191. Sato Y., Kanno S., Oda N., Abe M., Ito M., Shitara K., Shibuya M. Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction. Ann. N.Y. Acad. Sci. 902:2000;201-205. (discussion 205-7).
192. Seetharam L., Gotoh N., Maru Y., Neufeld G., Yamaguchi S., Shibuya M. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene. 10:1995;135-147.
193. Landgren E., Schiller P., Cao Y., Claesson-Welsh L. Placental growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt-1. Oncogene. 16:1998;359-367.
194. Zeng H., Dvorak H.F., Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) receptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J. Biol. Chem. 276:2001;26969-26979.
195. Zeng H., Zhao D., Mukhopadhyay D. KDR stimulates endothelial cell migration through heterotrimeric G protein Gq/11-mediated activation of a small GTPase RhoA. J. Biol. Chem. 277:2002;46791-46798.
196. Gille H., Kowalski J., Yu L., Chen H., Pisabarro M.T., Davis-Smyth T., Ferrara N. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3′-kinase activation and endothelial cell migration. EMBO J. 19:2000;4064-4073.
197. Yang S., Toy K., Ingle G., Zlot C., Williams P.M., Fuh G., Li B., de Vos A., Gerritsen M.E. Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of KDR and Flt-1 receptors. Arterioscler. Thromb. Vasc. Biol. 22:2002;1797-1803.
198. Rahimi N., Dayanir V., Lashkari K. Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J. Biol. Chem. 275:2000;16986-16992.
199. Kanno S., Oda N., Abe M., Terai Y., Ito M., Shitara K., Tabayashi K., Shibuya M., Sato Y. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene. 19:2000;2138-2146.
200. Fong G.H., Rossant J., Gertsenstein M., Breitman M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 376:1995;66-70.
201. Hiratsuka S., Minowa O., Kuno J., Noda T., Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. U. S. A. 95:1998;9349-9354.
202. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol., Cell Physiol. 280:2001;C1358-C1366.
203. Autiero M., Waltenberger J., Communi D., Kranz A., Moons L., Lambrechts D., Kroll J., Plaisance S., De Mol M., Bono F., Kliche S., Fellbrich G., Ballmer-Hofer K., Maglione D., Mayr-Beyrle U., Dewerchin M., Dombrowski S., Stanimirovic D., Van Hummelen P., Dehio C., Hicklin D.J., Persico G., Herbert J.M., Shibuya M., Collen D., Conway E.M., Carmeliet P. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat. Med. 9:2003;936-943.
204. Green C.J., Lichtlen P., Huynh N.T., Yanovsky M., Laderoute K.R., Schaffner W., Murphy B.J. Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1. Cancer Res. 61:2001;2696-2703.
205. Sawano A., Iwai S., Sakurai Y., Ito M., Shitara K., Nakahata T., Shibuya M. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood. 97:2001;785-791.
206. Hiratsuka S., Maru Y., Okada A., Seiki M., Noda T., Shibuya M. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res. 61:2001;1207-1213.
207. Odorisio T., Schietroma C., Zaccaria M.L., Cianfarani F., Tiveron C., Tatangelo L., Failla C.M., Zambruno G. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J. Cell. Sci. 115:2002;2559-2567.
208. Parenti A., Brogelli L., Filippi S., Donnini S., Ledda F. Effect of hypoxia and endothelial loss on vascular smooth muscle cell responsiveness to VEGF-A: role of flt-1/VEGF-receptor-1. Cardiovasc. Res. 55:2002;201-212.
209. Oura H., Bertoncini J., Velasco P., Brown L.F., Carmeliet P., Detmar M. A critical role of placental growth factor in the induction of inflammation and edema formation. Blood. 101:2003;560-567.
210. Marx G.M., Steer C.B., Harper P., Pavlakis N., Rixe O., Khayat D. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! J. Clin. Oncol. 20:2002;1446-1448.
211. Weng D.E., Usman N. Angiozyme: a novel angiogenesis inhibitor. Curr. Oncol. Rep. 3:2001;141-146.
212. Lu D., Jimenez X., Zhang H., Wu Y., Bohlen P., Witte L., Zhu Z. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. Cancer Res. 61:2001;7002-7008.